🇺🇸 FDA

Intelligence Platform

Patents

Browse 750 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 10400225

TAL effector-mediated DNA modification

Regents of the University of Minnesota · Granted Tue Sep 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10391152

Methods of using a fixed dose of a clotting factor

BIOVERATIV THERAPEUTICS INC. · Granted Tue Aug 27 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10391157

Materials and methods for producing improved lentiviral vector particles

IMMUNE DESIGN CORP. · Granted Tue Aug 27 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10392434

Treating refractory migraine

TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Tue Aug 27 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10376495

Small molecules that mimic or antagonize actions of granulocyte colony-stimulating-factor

The United States Government as Represented by the Department of Veterans · Granted Tue Aug 13 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 08 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10369192

Methods and compositions for delivery of exogenous factors to nervous system sites

REGENERATIVE RESEARCH FOUNDATION · Granted Tue Aug 06 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10370679

Modified immunization vectors

ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Tue Aug 06 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10370348

Tocopherol and tocopheryl quinone derivatives as correctors of lysosomal storage disorders

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Aug 06 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10370430

Recombinant factor VIII proteins

BIOVERATIV THERAPEUTICS INC. · Granted Tue Aug 06 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10370680

Method of treating factor IX deficiency using nuclease-mediated targeted integration

Sangamo Therapeutics, Inc. · Granted Tue Aug 06 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10322118

Compounds and methods for inhibiting Cif virulence factor

THE REGENTS OF TE UNIVERSITY OF CALIFORNIA · Granted Tue Jun 18 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 13 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10308941

Compositions and methods for inhibiting gene expression of factor XII

Arrowhead Pharmaceuticals, Inc. · Granted Tue Jun 04 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10294483

Eimeria tenella elongation factor-1 alpha recombinant immunogenic compositions which induc

The United States of America, as represented by the Secretary of Agriculture · Granted Tue May 21 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 16 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10280423

Compositions and methods for modulating complement factor B expression

Ionis Pharmaceuticals, Inc. · Granted Tue May 07 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 02 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10273274

Compositions and methods for inhibiting tumor cells by inhibiting the transcription factor

The Regents of the University of California · Granted Tue Apr 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10272163

Factor VIII mutation repair and tolerance induction

THE UNITED STATES OF AMERICA REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS · Granted Tue Apr 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10273228

Hepatitis B viral assembly effectors

ASSEMBLY BIOSCIENCES, INC. · Granted Tue Apr 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10265405

Polymers for delivery of factor VIII and/or factor IX

The Board of Regents of the University of Texas System · Granted Tue Apr 23 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10246463

Hypoxia-inducible factor 1 (HIF-1) inhibitors

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Apr 02 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10221455

Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VI

BIOVERATIV THERAPEUTICS INC. · Granted Tue Mar 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10221243

Methods of treating conditions with antibodies that bind colony stimulating factor 1 recep

Five Prime Therapeutics, Inc. · Granted Tue Mar 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10202618

Method of treating type I diabetes using an AAV vector encoding uracortin 2

The Regents of the University of California · Granted Tue Feb 12 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10201597

Codon-optimized lentiviral vector for stem cell reprogramming

The Regents of the University of California · Granted Tue Feb 12 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10202595

Chimeric clotting factors

BIOVERATIV THERAPEUTICS INC. · Granted Tue Feb 12 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted